The global idiopathic thrombocytopenic purpura therapeutics market is expected to reach USD 914.9 million by 2030, expanding at a CAGR of 5.0% from 2023 to 2030, according to a new report by Grand View Research, Inc.  Rising R&D leading to the introduction of new drugs for IVIG and TPO-RA classes is expected to propel growth over the forecast period. In addition, government...